Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients

被引：34
|
作者：
Reardon, David A.
Nayak, Lakshmi
Peters, Katherine B.
Clarke, Jennifer Leigh
Jordan, Justin T.
De Groot, John Frederick
Nghiemphu, Phioanh Leia
Kaley, Thomas Joseph
Colman, Howard
Gaffey, Sarah C.
Caruso, Victoria
Debruyne, Myriam Bednarek
Bhavsar, Chinmay
Molinaro, Annette M.
Smith, Timothy
Severgnini, Mariano
Wen, Patrick Y.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Massachusetts Gen Hosp, Boston, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Neuro Oncol, Houston, TX USA
[7] Univ Calif Los Angeles, Los Angeles, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Hunstman Canc Inst, Salt Lake City, UT USA
[10] Harvard Med Sch, Dana Farber, Brigham & Womens Canc Ctr, Boston, MA USA
[11] UC San Francisco, San Francisco, CA USA
[12] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
    Sathornsumetee, S.
    Vredenburgh, J. J.
    Rich, J. N.
    Desjardins, A.
    Quinn, J. A.
    Mathe, A. E.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
    Ahluwalia, Manmeet Singh
    Rauf, Yasmeen
    Li, Hong
    Wen, Patrick Y.
    Peereboom, David M.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
    Ahluwalia, Manmeet
    Khosla, Atulya
    Rauf, Yasmeen
    Peereboom, David
    Wen, Patrick Y.
    Reardon, David A.
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [24] Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
    He, Aiwu Ruth
    Weinberg, Benjamin Adam
    Noel, Marcus Smith
    Milic, Violeta P.
    Prins, Petra
    Wang, Hongkun
    Hartley, Marion L.
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] PHASE II STUDY OF BI-WEEKLY TEMOZOLOMIDE PLUS BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Badruddoja, Michael A.
    Pazzi, Marjorie
    Stea, Baldassarre
    Lefferts, Patricia
    Contreras, Nancy
    Wallen, Kelly
    Shah, Rajul
    Rance, Naomi
    Schroeder, Kurt
    Sanan, Abhay
    NEURO-ONCOLOGY, 2012, 14 : 102 - 102
  • [27] Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
    Michael A. Badruddoja
    Marjorie Pazzi
    Abhay Sanan
    Kurt Schroeder
    Kevin Kuzma
    Thomas Norton
    Thomas Scully
    Daruka Mahadevan
    Michael Malek Ahmadi
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 223 - 223
  • [28] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Dixit, Karan
    Kumthekar, Priya
    Kruser, Timothy
    Bloch, Orin
    Chandler, James
    Tate, Matthew
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2016, 18 : 19 - 19
  • [29] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [30] PHASE 2 STUDY OF PEMBROLIZUMAB PLUS TTFIELDS PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)
    Tran, David
    Ghinaseddin, Ashley
    Chen, Dongjiang
    Rahman, Maryam
    NEURO-ONCOLOGY, 2021, 23 : 53 - 53
12345